Day: February 11, 2021

ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) —  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica “Freddi” O’Brien, President of CFO’Brien Consulting, LLC, to its Board of Directors. Federica O’Brien is a veteran executive with 25 years of financial and operational leadership in biopharmaceutical, medical device, and technology companies and currently serves on the Board of Directors of TELA Bio, Inc. where she also chairs the Audit Committee. Ms. O’Brien will be joining MacroGenics’ Audit Committee.“We are delighted to welcome Ms. O’Brien to the Board. She is a highly experienced financial and strategic leader in our industry and will prove invaluable...

TORONTO, Feb. 11, 2021 (GLOBE NEWSWIRE) — YAMANA GOLD INC. (TSX:YRI; NYSE:AUY; LSE:AUY) (“Yamana” or the “Company”) declares a first quarter dividend of $0.02625 per share (annual $0.105 per share). Shareholders of record at the close of business on March 31, 2021, will be entitled to receive payment of this dividend on April 14, 2021. The dividend is an “eligible dividend” for Canadian tax purposes.About YamanaYamana Gold Inc. is a Canadian-based precious metals producer with significant gold and silver production, development stage properties, exploration properties, and land positions throughout the Americas, including Canada, Brazil, Chile and Argentina. Yamana plans to continue to build on this base through expansion and optimization initiatives at existing operating mines, development of new mines, the advancement of its exploration...

TORONTO, Feb. 11, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021 at 12:00 p.m. ET.The fireside chat will be broadcast live and archived on the Company’s website at www.profoundmedical.com under “Webcasts” in the Investors section.About Profound Medical Corp.Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.Profound is commercializing TULSA-PRO®, a...

VICTOR, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ) (“Constellation”) has been notified of an unsolicited “mini-tender” offer by TRC Capital Investment Corporation (“TRC”) to purchase up to 500,000 shares, or approximately 0.29 percent, of Constellation’s outstanding Class A common stock at a price of $210.00 per share in cash. TRC’s unsolicited offer price is approximately 5 percent less than the $219.99 closing price of Constellation’s Class A common stock on January 15, 2021, the last trading day prior to the commencement of the mini-tender offer. Furthermore, TRC’s unsolicited offer price is approximately 13 percent less than the $240.34 closing price of Constellation’s Class A common stock on February 10, 2021.Constellation is not associated in any way with TRC, TRC’s mini-tender offer or TRC’s...

SAN JOSE, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) — Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced it will release financial results for the fourth quarter and full year 2020 after market close on February 25, 2021. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights.Interested parties may access the live call via telephone by dialing (833) 649-1234 for domestic callers or (914) 987-7293 for international callers, using conference ID: 3033109. The live webinar of the call may also be accessed by visiting the Events and Presentations section of Eargo’s website at ir.eargo.com. A replay of the webinar will be available shortly...

EL DORADO, Ark., Feb. 11, 2021 (GLOBE NEWSWIRE) — The Board of Directors of Murphy USA Inc. (NYSE: MUSA) today declared a quarterly cash dividend on the Common Stock of Murphy USA Inc. of $0.25 per share, or $1.00 per share on an annualized basis. The dividend is payable on March 4, 2021, to stockholders of record as of February 22, 2021.About Murphy USAMurphy USA (NYSE: MUSA) is a leading retailer of gasoline and convenience merchandise with more than 1,650 stations located primarily in the Southwest, Southeast, Midwest, and Northeast United States. The company and its team of nearly 15,000 employees serve an estimated 2.0 million customers each day through its network of retail gasoline and convenience stations in 27 states. The majority of Murphy USA’s sites are located in close proximity to Walmart stores. The company...

MARIETTA, Ga., Feb. 11, 2021 (GLOBE NEWSWIRE) — BlueLinx Holdings Inc. (NYSE:BXC), a leading distributor of building and industrial products in the United States, today announced that Carol B. Yancey, the Executive Vice President and Chief Financial Officer of Genuine Parts Co. (“GPC”), a company listed on the New York Stock Exchange, has been appointed to BlueLinx’s Board of Directors, effective February 15, 2021. In addition, Carol will serve as a member of the board’s audit and nominating and corporate governance committees for the duration of her term.“We are excited to welcome Carol as our newest independent director to the BlueLinx board of directors,” said Kim Fennebresque, chairman of the board. “Carol will complement the skills and experience of our current board members as we move forward in achieving our short and long-term...

Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD)Strengthened Balance Sheet upon closing of $100 million underwritten public offeringSOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) — VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today reported its financial results for its fiscal 2021 third quarter ended December 31, 2020, and provided an update on planned clinical advancement of its CNS pipeline throughout the remainder of this calendar...